Literature DB >> 26152640

Cytokines in the immunopathology of systemic sclerosis.

Jasmin Raja1, Christopher Paul Denton.   

Abstract

Cytokines and growth factors are key regulators of immune activation, vascular alteration and excessive production of extracellular matrix which are hallmark events in the pathogenesis of systemic sclerosis (SSc). They modulate cell-cell and cell-matrix interactions. In particular, cytokines play a central role in the immunopathogenesis of SSc on the basis of molecular pathways which are complex and not completely understood. The majority of cytokines that may be involved in SSc pathogenesis have effect upon or are derived from cells of the immune system, including both the innate and adaptive compartments. Novel therapies that block key mediators that drive the fibrotic response are being developed and appear as potential therapeutic tools in the treatment of SSc, highlighting the importance for an effective therapy targeted towards the molecular and cellular pathways. This article reviews cytokine biology in that context, with particular emphasis on immunopathology of the disease, therapeutic targeting and the way that current or emerging treatments for SSc might impact on cytokine biology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26152640     DOI: 10.1007/s00281-015-0511-7

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  147 in total

1.  Defective vasculogenesis in systemic sclerosis.

Authors:  Masataka Kuwana; Yuka Okazaki; Hidekata Yasuoka; Yutaka Kawakami; Yasuo Ikeda
Journal:  Lancet       Date:  2004 Aug 14-20       Impact factor: 79.321

2.  CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production.

Authors:  Paola Romagnani; Laura Maggi; Benedetta Mazzinghi; Lorenzo Cosmi; Laura Lasagni; Francesco Liotta; Elena Lazzeri; Roberta Angeli; Mario Rotondi; Lucia Filì; Paola Parronchi; Mario Serio; Enrico Maggi; Sergio Romagnani; Francesco Annunziato
Journal:  J Allergy Clin Immunol       Date:  2005-12       Impact factor: 10.793

Review 3.  Targeted therapies for systemic sclerosis.

Authors:  Christopher P Denton; Voon H Ong
Journal:  Nat Rev Rheumatol       Date:  2013-04-09       Impact factor: 20.543

4.  Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo.

Authors:  T Arai; K Abe; H Matsuoka; M Yoshida; M Mori; S Goya; H Kida; K Nishino; T Osaki; I Tachibana; Y Kaneda; S Hayashi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-05       Impact factor: 5.464

5.  Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.

Authors:  David B Badesch; Nicholas S Hill; Gary Burgess; Lewis J Rubin; Robyn J Barst; Nazzareno Galiè; Gerald Simonneau
Journal:  J Rheumatol       Date:  2007-11-01       Impact factor: 4.666

Review 6.  Role of PDGF in fibrotic diseases and systemic sclerosis.

Authors:  M Trojanowska
Journal:  Rheumatology (Oxford)       Date:  2008-10       Impact factor: 7.580

7.  Antiangiogenic plasma activity in patients with systemic sclerosis.

Authors:  Mary Jo Mulligan-Kehoe; Mary C Drinane; Jessica Mollmark; Livia Casciola-Rosen; Laura K Hummers; Amy Hall; Antony Rosen; Fredrick M Wigley; Michael Simons
Journal:  Arthritis Rheum       Date:  2007-10

8.  Iloprost modulates the immune response in systemic sclerosis.

Authors:  Patrizia D'Amelio; Maria A Cristofaro; Lucia D'Amico; Luciana Veneziano; Ilaria Roato; Francesca Sassi; Giuseppina Bisignano; Marta Saracco; Raffaele Pellerito; Salvatore Patanè; Riccardo Ferracini; Gian P Pescarmona; Giovanni C Isaia
Journal:  BMC Immunol       Date:  2010-12-15       Impact factor: 3.615

Review 9.  Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.

Authors:  M Kathryn Steiner; Ioana R Preston
Journal:  Vasc Health Risk Manag       Date:  2008

Review 10.  Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis.

Authors:  Alisa E Koch; Oliver Distler
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more
  12 in total

1.  [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms].

Authors:  H L Zhu; Q DU; W L Chen; X X Zuo; Q Z Li; S J Liu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

Review 2.  Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.

Authors:  S Kumar; J Singh; S Rattan; A J DiMarino; S Cohen; S A Jimenez
Journal:  Aliment Pharmacol Ther       Date:  2017-02-09       Impact factor: 8.171

3.  Expression of TLR7, TLR9, JAK2, and STAT3 genes in peripheral blood mononuclear cells from patients with systemic sclerosis.

Authors:  Miša Vreća; Ana Zeković; Nemanja Damjanov; Marina Andjelković; Milena Ugrin; Sonja Pavlović; Vesna Spasovski
Journal:  J Appl Genet       Date:  2017-11-16       Impact factor: 3.240

Review 4.  Gastrointestinal and Hepatic Disease in Systemic Sclerosis.

Authors:  Tracy M Frech; Diane Mar
Journal:  Rheum Dis Clin North Am       Date:  2018-02       Impact factor: 2.670

5.  Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives.

Authors:  Fabian A Mendoza; Maryah Mansoor; Sergio A Jimenez
Journal:  Expert Opin Orphan Drugs       Date:  2015-11-23       Impact factor: 0.694

6.  Transforming growth factor-β signaling in systemic sclerosis.

Authors:  Nolan B Ayers; Chen-Ming Sun; Shi-You Chen
Journal:  J Biomed Res       Date:  2018-01-18

Review 7.  Emerging Roles of Matricellular Proteins in Systemic Sclerosis.

Authors:  Daniel Feng; Casimiro Gerarduzzi
Journal:  Int J Mol Sci       Date:  2020-07-06       Impact factor: 5.923

8.  Transcriptional insights into pathogenesis of cutaneous systemic sclerosis using pathway driven meta-analysis assisted by machine learning methods.

Authors:  Xiao Xu; Meera Ramanujam; Sudha Visvanathan; Shervin Assassi; Zheng Liu; Li Li
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240

9.  JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis.

Authors:  Zhanying Hou; Xuehan Su; Guangming Han; Ruzeng Xue; Yangxia Chen; Ye Chen; Huan Wang; Bin Yang; Yunsheng Liang; Suyun Ji
Journal:  Front Med (Lausanne)       Date:  2022-06-06

Review 10.  Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases.

Authors:  Rui Guo; Lan Li; Jing Su; Sheng Li; Sophia Esi Duncan; Zhihao Liu; Guanwei Fan
Journal:  Drug Des Devel Ther       Date:  2020-11-05       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.